千金药业：盐酸鲁拉西酮片获得药品注册证书

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Product Development - The Lurasidone Hydrochloride Tablets are indicated for the treatment of schizophrenia, originally developed by Sunovion Pharmaceuticals Inc. and launched in the U.S. in October 2010 [1] - The drug was approved for importation into China in January 2019, highlighting its potential in the domestic market [1] Group 2: Market Context - Other companies that have obtained the drug registration certificate in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] - According to data from MoSheng Pharmaceuticals, the estimated domestic market sales for Lurasidone Hydrochloride Tablets are approximately 52 million yuan in the first half of 2025, indicating a growing market opportunity [1]